Scientists dive deep into rare lung Cancer's genetic and immune secrets
NCT ID NCT07207278
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This study examines tumor samples from 39 Chinese patients with a rare lung cancer called signet ring cell carcinoma. Researchers will analyze genes and immune cells to build a detailed molecular database. A small group with specific genetic changes will also receive targeted drugs to see how well they work. The goal is to improve future diagnosis and personalized treatment for this cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SIGNET RING CELL CARCINOMA OF THE LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre of Translational Medicine, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tyrosine kinase inhibitors (alectinib or crizotinib)
What this could lead to
If successful, this could identify new biomarkers and immune profiles to personalize treatment for lung signet ring cell carcinoma in Chinese patients.
What could go wrong
This is a small, early-stage study with only 39 participants, so results may not apply broadly. The focus is on understanding the disease, not testing a new treatment directly.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.